vs
Side-by-side financial comparison of BIOMARIN PHARMACEUTICAL INC (BMRN) and Evogene Ltd. (EVGN), based on the latest 10-Q / 10-K filings. Click either name above to swap in a different company.
BIOMARIN PHARMACEUTICAL INC is the larger business by last-quarter revenue ($874.6M vs $3.2M, roughly 271.0× Evogene Ltd.). BIOMARIN PHARMACEUTICAL INC runs the higher net margin — -5.3% vs -237.7%, a 232.4% gap on every dollar of revenue. On growth, Evogene Ltd. posted the faster year-over-year revenue change (40.7% vs 17.0%).
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technolo...
BMRN vs EVGN — Head-to-Head
Income Statement — Q4 2025 vs Q2 2025
| Metric | | |
|---|---|---|
| Revenue | $874.6M | $3.2M |
| Net Profit | $-46.6M | $-7.7M |
| Gross Margin | 68.5% | 48.8% |
| Operating Margin | -5.1% | -189.0% |
| Net Margin | -5.3% | -237.7% |
| Revenue YoY | 17.0% | 40.7% |
| Net Profit YoY | -137.3% | 22.0% |
| EPS (diluted) | $-0.22 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align — see 8-quarter trend below.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history — bar widths are scaled to the larger of the two companies so you can eyeball the size gap and growth trajectory without doing math. Quarters aligned by calendar period (report date) so offset fiscal years line up.
| Q4 25 | $874.6M | — | ||
| Q3 25 | $776.1M | — | ||
| Q2 25 | $825.4M | $3.2M | ||
| Q1 25 | $745.1M | — | ||
| Q4 24 | $747.3M | — | ||
| Q3 24 | $745.7M | — | ||
| Q2 24 | $712.0M | $2.3M | ||
| Q1 24 | $648.8M | — |
| Q4 25 | $-46.6M | — | ||
| Q3 25 | $-30.7M | — | ||
| Q2 25 | $240.5M | $-7.7M | ||
| Q1 25 | $185.7M | — | ||
| Q4 24 | $124.9M | — | ||
| Q3 24 | $106.1M | — | ||
| Q2 24 | $107.2M | $-9.8M | ||
| Q1 24 | $88.7M | — |
| Q4 25 | 68.5% | — | ||
| Q3 25 | 82.0% | — | ||
| Q2 25 | 81.8% | 48.8% | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 81.8% | — | ||
| Q3 24 | 74.7% | — | ||
| Q2 24 | 81.7% | 71.8% | ||
| Q1 24 | 80.7% | — |
| Q4 25 | -5.1% | — | ||
| Q3 25 | -6.0% | — | ||
| Q2 25 | 33.5% | -189.0% | ||
| Q1 25 | 30.0% | — | ||
| Q4 24 | 21.6% | — | ||
| Q3 24 | 15.3% | — | ||
| Q2 24 | 16.9% | -409.9% | ||
| Q1 24 | 13.6% | — |
| Q4 25 | -5.3% | — | ||
| Q3 25 | -4.0% | — | ||
| Q2 25 | 29.1% | -237.7% | ||
| Q1 25 | 24.9% | — | ||
| Q4 24 | 16.7% | — | ||
| Q3 24 | 14.2% | — | ||
| Q2 24 | 15.1% | -428.5% | ||
| Q1 24 | 13.7% | — |
| Q4 25 | $-0.22 | — | ||
| Q3 25 | $-0.16 | — | ||
| Q2 25 | $1.23 | — | ||
| Q1 25 | $0.95 | — | ||
| Q4 24 | $0.65 | — | ||
| Q3 24 | $0.55 | — | ||
| Q2 24 | $0.55 | $-1.82 | ||
| Q1 24 | $0.46 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest filing — the kind of financial-strength check premium terminals charge for.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $8.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $6.1B | $12.4M |
| Total Assets | $7.6B | $33.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | $8.3M | ||
| Q1 25 | $1.0B | — | ||
| Q4 24 | $942.8M | — | ||
| Q3 24 | $675.4M | — | ||
| Q2 24 | $972.1M | $9.5M | ||
| Q1 24 | $747.0M | — |
| Q4 25 | $6.1B | — | ||
| Q3 25 | $6.1B | — | ||
| Q2 25 | $6.0B | $12.4M | ||
| Q1 25 | $5.8B | — | ||
| Q4 24 | $5.7B | — | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $5.3B | $19.9M | ||
| Q1 24 | $5.1B | — |
| Q4 25 | $7.6B | — | ||
| Q3 25 | $7.6B | — | ||
| Q2 25 | $7.5B | $33.9M | ||
| Q1 25 | $7.1B | — | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $6.9B | — | ||
| Q2 24 | $7.1B | $41.0M | ||
| Q1 24 | $6.9B | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Net income can be massaged; cash flow is harder to fake.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $99.6M | $-7.5M |
| Free Cash FlowOCF − Capex | $58.9M | — |
| FCF MarginFCF / Revenue | 6.7% | — |
| Capex IntensityCapex / Revenue; lower = less reinvestment burden | 4.7% | — |
| Cash ConversionOCF / Net Profit; >1× = earnings back up with cash | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $725.0M | — |
8-quarter trend — quarters aligned by calendar period so offset fiscal years match up.
| Q4 25 | $99.6M | — | ||
| Q3 25 | $368.7M | — | ||
| Q2 25 | $185.3M | $-7.5M | ||
| Q1 25 | $174.4M | — | ||
| Q4 24 | $185.6M | — | ||
| Q3 24 | $221.5M | — | ||
| Q2 24 | $118.8M | $-9.6M | ||
| Q1 24 | $47.0M | — |
| Q4 25 | $58.9M | — | ||
| Q3 25 | $340.2M | — | ||
| Q2 25 | $168.2M | — | ||
| Q1 25 | $157.6M | — | ||
| Q4 24 | $166.1M | — | ||
| Q3 24 | $203.0M | — | ||
| Q2 24 | $97.4M | — | ||
| Q1 24 | $20.9M | — |
| Q4 25 | 6.7% | — | ||
| Q3 25 | 43.8% | — | ||
| Q2 25 | 20.4% | — | ||
| Q1 25 | 21.2% | — | ||
| Q4 24 | 22.2% | — | ||
| Q3 24 | 27.2% | — | ||
| Q2 24 | 13.7% | — | ||
| Q1 24 | 3.2% | — |
| Q4 25 | 4.7% | — | ||
| Q3 25 | 3.7% | — | ||
| Q2 25 | 2.1% | — | ||
| Q1 25 | 2.3% | — | ||
| Q4 24 | 2.6% | — | ||
| Q3 24 | 2.5% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 4.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.94× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 2.09× | — | ||
| Q2 24 | 1.11× | — | ||
| Q1 24 | 0.53× | — |
Financial Flow Comparison
Sankey diagram of revenue → gross profit → operating profit → net profit for each company. Charts shown full-width and stacked so both segment hierarchies are readable side-by-side on desktop and mobile.
Revenue Breakdown by Segment
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
EVGN
Segment breakdown not available.
